Results of the Combined General Shareholders’ Meeting of June 30, 2021
01/07/2021 – AB Science announces today the results of the Combined General Shareholders’ Meeting of June 30, 2021
Signature of an agreement with historical shareholders to implement a joint strategy to increase the value of masitinib
28/06/2021 – AB Science announced today that it has signed an agreement with historical shareholders to implement a joint strategy to increase the value of masitinib
Results from masitinib study AB12005 in pancreatic cancer have been presented at the 2021 ASCO Annual Meeting
10/06/2021 – AB Science today announced that results from masitinib study AB12005 in pancreatic cancer have been presented at the 2021 ASCO Annual Meeting
Summary of the live webcast held on June 3, 2021 following the voluntary hold in the clinical studies of masitinib
08/06/2021 – AB Science is providing a summary of the live webcast held on June 3, 2021 following the voluntary hold in the clinical studies of masitinib
Live webcast on Thursday June 3, 2021 following the voluntary hold in the clinical studies of masitinib
02/06/2021 – AB Science will host a live webcast on June 3, 2021 to provide details on the decision to suspend voluntarily the clinical studies with masitinib
AB Science announces a voluntary hold in the clinical studies of masitinib
01/06/2021 – AB Science announced today that it has taken the decision to suspend inclusions and treatment initiation in its clinical studies with masitinib worldwide
Results from Phase 3 study evaluating masitinib in prostate cancer
26/05/2021 – AB Science communicated the results from Phase 3 study evaluating masitinib in prostate cancer during the webcast that was held on May 25, 2021
Live webcast on Tuesday May 25, 2021 on masitinib’s results in prostate cancer
21/05/2021 – AB Science will host a live webcast on May 25, 2021 to discuss recently reported results from the Phase 2B/3 masitinib trial in prostate cancer
Results from masitinib study AB12005 in pancreatic cancer selected for presentation at the ASCO Annual Meeting
20/05/2021 – AB Science today announced that results from masitinib study AB12005 in pancreatic cancer, have been selected for presentation at the upcoming ASCO Annual Meeting
Annual financial results as of 31 December, 2020
30/04/2021 – AB Science reports its annual financial results as of 31 December, 2020